tetano
Editor, Senior Moderator
Cureus. 2020 Mar 25;12(3):e7415. doi: 10.7759/cureus.7415.
Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?
Sharma M[SUP]1[/SUP], Surani S[SUP]2,[/SUP][SUP]1,[/SUP][SUP]3[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First reported at the end of December 2019 as a cause for clusters of pneumonia cases in Wuhan city in China, the rapid spread of this condition was declared a pandemic on March 11, 2020, by the World Health Organization (WHO). Apart from the mortality and morbidity associated with COVID-19, the massive social and financial havoc inflicted by this pandemic has left the entire world pondering if medical science can innovate and curtail the ongoing damage due to SARS-CoV-2. Recent findings of an open-label study that investigated the use of hydroxychloroquine and azithromycin in COVID-19 patients in Marseille, France, has garnered some optimism in scientific quarters and the general public alike in terms of finding a treatment regimen to control the rampant rise of COVID-19. We will discuss the potential off-label therapy and studies as it pertains to COVID-19.
Copyright ? 2020, Sharma et al.
KEYWORDS:
azithromycin; coronavirus disease; hydroxychloroquine; sars-cov-2 (severe acute respiratory syndrome coronavirus -2)
PMID:32337139PMCID:PMC7182165DOI:10.7759/cureus.7415
Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?
Sharma M[SUP]1[/SUP], Surani S[SUP]2,[/SUP][SUP]1,[/SUP][SUP]3[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First reported at the end of December 2019 as a cause for clusters of pneumonia cases in Wuhan city in China, the rapid spread of this condition was declared a pandemic on March 11, 2020, by the World Health Organization (WHO). Apart from the mortality and morbidity associated with COVID-19, the massive social and financial havoc inflicted by this pandemic has left the entire world pondering if medical science can innovate and curtail the ongoing damage due to SARS-CoV-2. Recent findings of an open-label study that investigated the use of hydroxychloroquine and azithromycin in COVID-19 patients in Marseille, France, has garnered some optimism in scientific quarters and the general public alike in terms of finding a treatment regimen to control the rampant rise of COVID-19. We will discuss the potential off-label therapy and studies as it pertains to COVID-19.
Copyright ? 2020, Sharma et al.
KEYWORDS:
azithromycin; coronavirus disease; hydroxychloroquine; sars-cov-2 (severe acute respiratory syndrome coronavirus -2)
PMID:32337139PMCID:PMC7182165DOI:10.7759/cureus.7415